drugset / Trial / NCT07513454
A Phase 2 Study of HW211026
Phase 2
Not yet recruiting
80 enrolled
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, open-label, parallel-group, Phase II clinical trial designed to evaluate the efficacy and safety of HW211026 in adult patients with actinic keratosis.
Timeline
- Start
- 2026-07
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HW211026 | Unknown | — | Topical |